GlassScriptPhysician profile
Danielle J Abrahamson
NPI 1235393117
$5,831.00
in general payments reported to CMS, 2019-2025
53 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $403 · 2022: $568 · 2023: $1,469 · 2024: $1,946 · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,633 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,632.58 |
| Education | $227.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $402.43 | 2021-2025 | Rybrevant, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $366.89 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Lilly USA, LLC | $339.59 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $319.77 | 2021-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $294.17 | 2021-2025 | |
| Pfizer INC. | $286.59 | 2021-2025 | |
| Abbvie INC. | $270.12 | 2022-2025 | Venclexta |
| Glaxosmithkline, LLC. | $259.74 | 2021-2025 | Ojjaara, Shingrix, Blenrep |
| Rigel Pharmaceuticals, INC. | $256.92 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Incyte Corporation | $237.80 | 2021-2025 | Jakafi, Monjuvi |
| Seagen INC. | $231.29 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Geron Corporation | $201.96 | 2025 | Rytelo |
| Merck Sharp & Dohme LLC | $172.21 | 2022-2025 | Keytruda, Lynparza, Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $158.57 | 2023-2024 | Alunbrig, Ninlaro, Fruzaqla |
| Sumitomo Pharma America, INC. | $152.02 | 2023-2025 | Orgovyx |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $146.93 | 2021-2025 | Enhertu, Calquence, Lynparza |
| Astellas Pharma US INC | $126.28 | 2022-2025 | Vyloy, Xtandi |
| Ipsen Biopharmaceuticals, INC | $119.65 | 2023-2025 | Onivyde, Tazverik, Somatuline Depot |
| Eisai INC. | $113.04 | 2021-2025 | |
| Celgene Corporation | $104.92 | 2021-2024 | Pomalyst, Reblozyl, Opdualag |
| Taiho Oncology, INC. | $96.34 | 2023-2025 | |
| Amgen INC. | $93.59 | 2021-2023 | Lumakras |
| E.R. Squibb & Sons, L.L.C. | $74.68 | 2022-2025 | Opdivo, Augtyro |
| Emd Serono, INC. | $64.02 | 2023-2024 | Bavencio |
| Pharmacosmos Therapeutics INC. | $60.96 | 2023-2024 | Monoferric, Cosela |
| Beigene USA, INC. | $57.90 | 2021-2024 | Tevimbra, Brukinsa |
| Springworks Therapeutics, INC. | $53.95 | 2024-2025 | Ogsiveo |
| Adc Therapeutics America, INC. | $52.21 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $50.56 | 2024-2025 | Libtayo |
| Genmab U.S., INC. | $49.58 | 2024-2025 | Epkinly |
| Tersera Therapeutics LLC | $45.43 | 2021-2024 | Zoladex, Xermelo |
| Array Biopharma INC | $43.87 | 2024-2025 | Lorbrena, Mektovi, Braftovi |
| Genzyme Corporation | $42.61 | 2023-2024 | |
| Genentech USA, INC. | $42.04 | 2025 | Tecentriq, Itovebi |
| Syndax Pharmaceuticals, INC. | $38.92 | 2025 | Revuforj |
| Aveo Pharmaceuticals, INC. | $37.32 | 2023-2024 | Fotivda |
| Tactile Systems Technology INC | $35.58 | 2021-2022 | |
| Blueprint Medicines Corporation | $34.28 | 2021-2023 | Ayvakit |
| Pharmaessentia USA Corporation | $30.47 | 2023 | Besremi |
| Sobi, INC | $29.10 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $28.91 | 2021-2025 | Ultomiris |
| Myriad Genetic Laboratories, INC. | $21.52 | 2023 | Bracanalysis Cdx |
| Morphosys, US INC. | $21.43 | 2023 | Monjuvi |
| Kyowa Kirin, INC. | $20.00 | 2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.64 | 2021 | |
| Stemline Therapeutics INC. | $17.50 | 2023 | Orserdu |
| Gilead Sciences, INC. | $17.07 | 2024 | Trodelvy |
| Jazz Pharmaceuticals INC. | $16.99 | 2022 | |
| Tolmar, INC. | $16.93 | 2024 | |
| Novocure INC. | $15.00 | 2025 | Optune Lua (Novottf-200t) |
| Deciphera Pharmaceuticals INC. | $14.91 | 2022 | |
| Beone Medicines USA, INC. | $13.84 | 2025 | Brukinsa |
| Foundation Medicine, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Abrahamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.